SE
Steve Elms (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in ADMA Biologics, Inc. (ADMA). Across 1 priced purchase filing, the average 21-session return was -44.2% from execution and -40.9% from disclosure (delay-adjusted; derived). The largest single filing was $217K of ADMA (14,000 sh across 2 lots, as filed), executed Mar 5. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-44.2%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-40.9%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$217K
shares × price, as filed
Last traded
Mar 6
Filed Mar 9
Median ADV $38.1M across their filed names
Open performance→Volume by month
Buys $217K
Sells $8.8M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
ADMARecent filings
ADMAPURCHASE
ADMA Biologics, Inc.
View filing →
$217K14,000 sh across 2 lots
Exec Mar 5
Filed Mar 9 · 9:14 AM ET ADMASALE ADMA Biologics, Inc. View filing → $8.8M
425,621 sh across 3 lots
Exec Jun 12 2025
Filed Jun 16 2025 · 5:30 PM ET